Alivus Life Sciences Ltd. (ALIVUS) fundamentals
Alivus Life Sciences Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as ALIVUS (ISIN INE03Q201024). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Alivus Life Sciences Ltd. does
Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, is an India-based developer and manufacturer of non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The Company is providing contract development and manufacturing (CDMO) services to a range of multinational and specialty pharmaceutical companies. Its primary therapy areas include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, oncology, pain management (anti-migraine, analgesic) and anti-infectives (antibiotic). It also develops APIs in the therapeutic areas such as antifungal, anti-histaminic, anti-acne, anti-emetic, ophthalmologic agent, urinary and anti-spasmodic. It has a diversified portfolio of around 151 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan and the rest of the world. Its four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh.
Valuation and market data
| Last close | ₹1386.80 |
|---|---|
| Market capitalisation | ₹17,022 crore |
| Enterprise value | ₹17,162 crore |
| P/E (TTM) | 30.15 |
| Price to book | 5.11 |
| Price to sales (TTM) | 3.78 |
| Book value per share | ₹271.48 |
| Dividend yield | 36.05% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri Aug 06 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹2,612 crore | ₹751 crore | ₹564 crore | 45.99 |
| Mar 2025 | ₹2,421 crore | ₹654 crore | ₹486 crore | 39.63 |
| Mar 2024 | ₹2,295 crore | ₹631 crore | ₹471 crore | 38.43 |
| Mar 2023 | ₹2,190 crore | ₹629 crore | ₹467 crore | 38.11 |
| Mar 2022 | ₹2,138 crore | ₹565 crore | ₹419 crore | 35.63 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 74.9% |
|---|---|
| Foreign institutions (FII) | 5.5% |
| Mutual funds | 5.7% |
| Other domestic institutions | 1.5% |
| Retail and others | 12.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.